Vaccines as Immunotherapies for Substance Use Disorders
Kosten T. Vaccines as Immunotherapies for Substance Use Disorders. American Journal Of Psychiatry 2024, 181: 362-371. PMID: 38706331, DOI: 10.1176/appi.ajp.20230828.Peer-Reviewed Original ResearchConceptsSubstance use disordersHuman clinical trials of vaccinesPreclinical vaccine studiesClinical trials of vaccinesVaccine clinical trialsHuman clinical trialsTrials of vaccinesVaccine immunotherapyIllicit fentanyl useOpioid pharmacotherapyEffective therapySubstance use disorder treatmentFentanyl useClinical trialsVaccine studiesAnimal modelsAnimal studiesUse disorderVaccine technologyLethal overdoseImmunotherapyVaccineLimited treatment accessFentanyl overdoseTreatment accessGinkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial
Wang D, Tian Y, Chen J, Zhu R, Li J, Zhou H, Chen D, Wang L, Kosten T, Zhang X. Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial. Current Neuropharmacology 2024, 22: 2443-2452. PMID: 38919004, PMCID: PMC11451319, DOI: 10.2174/1570159x22666240530095721.Peer-Reviewed Original ResearchAbnormal Involuntary Movement ScaleMnSOD Ala-9Val polymorphismTardive dyskinesiaTD patientsTD symptomsAla-9Val polymorphismPathophysiology of tardive dyskinesiaNon-TDHealthy controlsNon-TD patientsSeverity of TDMovement ScaleAla alleleDouble-blind clinical trialIncreased MnSOD activityMnSOD activityWeeks of treatmentVal/Val genotypeTreatment responseDyskinesiaGinkgo biloba extractEGb761 groupManganese superoxide dismutaseSymptomsClinical trials